We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

CureVac NV (CVAC) EUR0.12

Sell:$3.00 Buy:$3.14 Change: $0.12 (4.01%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.00
Buy:$3.14
Change: $0.12 (4.01%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.00
Buy:$3.14
Change: $0.12 (4.01%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Contact details

Address:
Friedrich-Miescher-Str. 15
TUEBINGEN
72076
Germany
Telephone:
+49 (7071) 98830
Website:
https://www.curevac.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CVAC
ISIN:
NL0015436031
Market cap:
$616.93 million
Shares in issue:
224.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Netherlands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Baron Stephenne
    Independent Chairman of Supervisory Board
  • Alexander Zehnder
    Chief Executive Officer, Member of the Management Board
  • Axel-Sven Malkomes
    Chief Financial Officer
  • Malte Greune
    Chief Operating Officer, Member of the Management Board
  • Antony Blanc
    Chief Commercial Officer, Member of the Management Board
  • Myriam Mendila
    Chief Development Officer, Member of the Management Board
  • Thaminda Ramanayake
    Chief Business Officer, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.